Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Sells $414,043.52 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 36,256 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $11.42, for a total transaction of $414,043.52. Following the completion of the transaction, the executive vice president now directly owns 735,074 shares of the company’s stock, valued at approximately $8,394,545.08. The trade was a 4.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

David Sponsel also recently made the following trade(s):

• On Monday, January 13th, David Sponsel sold 58,283 shares of Alphatec stock. The stock was sold at an average price of $10.71, for a total transaction of $624,210.93.
• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The stock was sold at an average price of $10.00, for a total transaction of $2,380.00.

Alphatec Price Performance

NASDAQ:ATEC traded up $0.68 during mid-day trading on Tuesday, reaching $12.14. 1,708,966 shares of the stock were exchanged, compared to its average volume of 1,845,308. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The business has a fifty day moving average price of $10.15 and a 200 day moving average price of $8.07. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $17.34. The firm has a market capitalization of $1.72 billion, a PE ratio of -9.48 and a beta of 1.43.

Institutional Trading of Alphatec

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sei Investments Co. grew its holdings in shares of Alphatec by 4.7% in the 2nd quarter. Sei Investments Co. now owns 111,460 shares of the medical technology company’s stock worth $1,165,000 after acquiring an additional 4,976 shares during the last quarter. AQR Capital Management LLC raised its holdings in Alphatec by 129.1% during the 2nd quarter. AQR Capital Management LLC now owns 283,254 shares of the medical technology company’s stock worth $2,960,000 after buying an additional 159,600 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Alphatec by 8.9% in the second quarter. The Manufacturers Life Insurance Company now owns 58,257 shares of the medical technology company’s stock worth $609,000 after buying an additional 4,755 shares during the period. Creative Planning raised its holdings in shares of Alphatec by 112.7% during the second quarter. Creative Planning now owns 26,440 shares of the medical technology company’s stock valued at $276,000 after acquiring an additional 14,007 shares during the period. Finally, SG Americas Securities LLC lifted its position in shares of Alphatec by 207.7% in the 3rd quarter. SG Americas Securities LLC now owns 44,603 shares of the medical technology company’s stock valued at $248,000 after acquiring an additional 30,108 shares in the last quarter. 66.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research note on Tuesday, January 14th. Needham & Company LLC raised their target price on Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Finally, Barclays increased their price target on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Alphatec has an average rating of “Moderate Buy” and a consensus price target of $17.56.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.